Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 2/20 | 0.49 |
| ▸ | GCK | P35557 | 2/20 | 0.47 |
| ▸ | PYGL | P06737 | 3/20 | 0.46 |
| ▸ | PYGM | P11217 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 10/20 | 0.44 |
| ▸ | BRAF | P15056 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330562 | 0.94 | GCK (0.50) | HSPB1GCKPYGLPYGMGAA | |
| SCHEMBL29251625 | 0.86 | GCK (0.52) | HSPB1GCKPYGLPYGMGAA | |
| SCHEMBL29251357 | 0.86 | GCK (0.47) | HSPB1GCKPYGLPYGMKDR | |
| SCHEMBL28593422 | 0.83 | GCK (0.47) | HSPB1GCKPYGLPYGMKDR | |
| SCHEMBL4335111 | 0.83 | GCK (0.49) | HSPB1GCKPYGLPYGMGAA | |
| SCHEMBL28352008 | 0.83 | KDR (0.59) | KDRBRAF | |
| SCHEMBL4730770 | 0.83 | GCK (0.43) | HSPB1GCKPYGLPYGMKDR | |
| SCHEMBL4330869 | 0.83 | GCK (0.55) | GCKPYGLPYGMGAAALDH1A1 | |
| SCHEMBL16895229 | 0.82 | KDR (0.59) | HSPB1GCKPYGLPYGMKDR | |
| SCHEMBL4329492 | 0.82 | MEN1 (0.55) | GCKPYGLPYGMGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| WO-2008046216-A1 | KINASE INHIBITORS AND USES THEREOF | METHYLGENE, INC. (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | HSPB1 3174/4885GCK 993/4885PYGL 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.